[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hepatopancreatobiliary Surgery Institute of Gansu Province\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":124},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,72,99],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100617654",false,"NCT07321431","The Optimal Measurement Time for the New Gallbladder Function Assessment Method","The Optimal Measurement Time for the New Gallbladder Function Assessment Method: A Prospective, Multicenter, Double-Blind, Crossover Trial","Inclusion Criteria:\n\n* Ultrasound assessment identifies people with normal biliary tract structure.\n\nExclusion Criteria:\n\n* History of Endoscopic Retrograde Cholangiopancreatography\n* Previous gallstone removal surgery with gallbladder preservation\n* Other biliary tract diseases and related surgical history\n* History of acute or chronic pancreatitis\n* History of gastrointestinal surgery\n* Gastrointestinal obstruction\n* Dysfunction of the sphincter of Oddi\n* Gallbladder neck polyps\n* Abnormal gallbladder structure\n* Gallbladder mass\n* Biliary infection or stones\n* Congenital biliary abnormalities\n* Biliary injury or surgery\n* Biliary tumors\n* Gastrointestinal bleeding, liver cirrhosis, or other malignant diseases\n* Significant arrhythmia, bradycardia, or atrioventricular block\n* Severe hypertension, liver or kidney insufficiency\n* Immune, endocrine, hematological, or mental disorders\n* Severe cerebrovascular disease\n* Allergy to relevant foods\n* Pregnant or breastfeeding women\n* Unwillingness or inability to consent to participation",true,"ALL","18 Years","70 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a multicenter, prospective, randomized, double-blind, crossover study involving healthy individuals, aiming to evaluate the stability of oral protein bars + olive oil as a new method for determining gallbladder contraction function and its optimal diagnostic time window.",[27],"Gallbladder; Functional Disturbance",[29,30,31,32,33],"Gallbladder Contractile Function","Ultrasound Examination","Olive oil","Protein Bar","Optimal time","RECRUITING","2026-01-06",{"date":37,"type":38},"2026-01-08","ACTUAL",{"date":40,"type":38},"2026-01-07",{"date":42,"type":21},"2026-12-20",{"name":44,"class":45},"Hepatopancreatobiliary Surgery Institute of Gansu Province","OTHER",5,{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100569806","NCT06699030","A Strategy for Gallstone Expulsion Through Dietary Therapy","A New Strategy for Gallstone Expulsion Through Dietary Therapy: A Prospective, Single-Center, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Gallbladder sludge-like stones with a maximum stone diameter of less than 2 mm\n\nExclusion Criteria:\n\n* History of ERCP (Endoscopic Retrograde Cholangiopancreatography)\n* Previous gallstone removal surgery with gallbladder preservation\n* History of acute or chronic pancreatitis, cholangitis\n* Mirizzi Syndrome\n* History of gastrointestinal surgery\n* Gastrointestinal obstruction\n* Dysfunction of the sphincter of Oddi\n* Gallbladder neck polyps\n* Abnormal gallbladder structure\n* Gallbladder mass\n* Biliary infection or stones\n* Congenital biliary abnormalities\n* Biliary injury or surgery\n* Biliary tumors\n* Gastrointestinal bleeding, liver cirrhosis, or other malignant diseases\n* Significant arrhythmia, bradycardia, or atrioventricular block\n* Severe hypertension, liver or kidney insufficiency\n* Immune, endocrine, hematological, or mental disorders\n* Severe cerebrovascular disease\n* Allergy to relevant foods\n* Pregnant or breastfeeding women\n* Unwillingness or inability to consent to participation",{"count":54,"type":21},100,[24],"This study is a double-blind, prospective, single-center controlled trial conducted at a tertiary hospital, aiming to determine whether dietary therapy can effectively expel gallstones.",[58],"Gallbladder Stone",[60,61,62,30],"Gallstone","Gallbladder Function","Cholecystitis","2025-12-24",{"date":65,"type":38},"2025-12-31",{"date":67,"type":38},"2024-12-24",{"date":69,"type":21},"2026-12-01",{"name":44,"class":45},1,{"id":73,"slug":4,"hasResults":10,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100293799","NCT03104569","Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma","Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma: A Prospective Double-blind Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n* Type Ⅰ、Ⅱ、Ⅲ、Ⅳ of Hilar Cholangiocarcinoma;\n* Age: 18\\~90 years old;\n* Underwent diagnostic and therapeutic ERCP;\n\nExclusion Criteria:\n\n* Coagulation dysfunction(INR\\>1.3) or\u002Fand low peripheral blood platelet count （PLT \\\u003C50x10\\^9\u002FL）;\n* Preoperative acute cholangitis;\n* Preoperative acute pancreatitis;\n* Preoperative hemobilia or hemorrhage of digestive tract;\n* Preoperative liver failure;\n* Combined with Mirizzi syndrome and intrahepatic bile duct stones;\n* Preoperative malignant tumor of biliary system such as carcinoma of head of pancreas, gallbladder carcinoma;\n* Biliary-duodenal fistula confirmed during ERCP;\n* A history of reconstructive surgery for upper digestive tract except Billroth Ⅰand a history of cholangioenterostomy including cholangio-jejunostomy and side to side anastomosis of the bile duct and duodenum;\n* Previous ERCP;\n* Pregnant women","90 Years",{"count":54,"type":21},[24],"The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.",[83],"Cholangitis",[85,86,87,83,88],"ERCP","Contrast agent","Hilar cholangiocarcinoma","Nonionic","NOT_YET_RECRUITING","2025-12-19",{"date":92,"type":38},"2025-12-26",{"date":94,"type":21},"2026-04-01",{"date":96,"type":21},"2028-12-01",{"name":44,"class":45},3,{"id":100,"slug":4,"hasResults":10,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":71},"100599979","NCT07091526","Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer","Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer","Inclusion Criteria:\n\n* Patients with pathologically confirmed pancreatic cancer (primary)\n* Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）\n* The postoperative survival time was at least 6 weeks\n\nExclusion Criteria:\n\n* No surgery was performed, or only palliative surgery\u002F biopsy was performed\n* Patients who underwent emergency hemodialysis or plasma exchange after surgery\n* History of gout or long-term urate-lowering therapy, such as allopurinol\n* Patients are missing follow-up data\n* Hydrochlorothiazide and furosemide were used\n* Chronic kidney disease\n* Oncolytic syndrome\n* Hemolytic anemia\n* Lead poisoning\n* Hyperparathyroidism\n* Hypothyroidism\n* A tyrosinase inhibitor was used\n* Patients with nonpancreatic primary tumors\n* Pregnant or postpartum women.","85 Years",{"count":107,"type":21},168,"OBSERVATIONAL","This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.",[111],"Serum Uric Acid",[113,114,115,116],"Serum uric acid","Pancreatic cancer","Pancreaticoduodenectomy","Distal pancreatectomy","2025-12-13",{"date":90,"type":38},{"date":120,"type":38},"2025-07-29",{"date":122,"type":21},"2026-12-29",{"name":44,"class":45},""]